Prolactin as a Potential Early Predictive Factor in Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab

Publisher： Karger

E-ISSN： 1423-0232|93|1|62-66

ISSN： 0030-2414

Source： Oncology, Vol.93, Iss.1, 2017-04, pp. : 62-66

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Immune Thrombocytopenia Induced by Nivolumab in a Metastatic Non-Small Cell Lung Cancer Patient

By  

Oncology Research and Treatment, Vol. 40, Iss. 10, 2017-09 ,pp. : 621-622

Karger

Access to resources Recommend Favorite

Gefitinib-Induced Hepatotoxicity in Patients Treated for Non-Small Cell Lung Cancer

By  

Oncology Research and Treatment, Vol. 35, Iss. 9, 2012-08 ,pp. : 509-513

Karger

Access to resources Recommend Favorite

Comprehensive Biomarker Analyses in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer Prospectively Treated with the Polo-Like Kinase 1 Inhibitor BI2536

By  

Oncology Research and Treatment, Vol. 40, Iss. 7-8, 2017-06 ,pp. : 435-439

Karger

Access to resources Recommend Favorite

Investigating the Potential of Bevacizumab in Other Indications: Metastatic Renal Cell, Non-Small Cell Lung, Pancreatic and Breast Cancer

By  

Oncology, Vol. 69, Iss. 3, 2005-11 ,pp. : 46-56

Karger

Access to resources Recommend Favorite

Predictive and Prognostic Value of Early Disease Progression by PET Evaluation in Advanced Non-Small Cell Lung Cancer

By  

Oncology, Vol. 92, Iss. 1, 2016-11 ,pp. : 39-47

Karger

Access to resources Recommend Favorite